Connect Biopharma Holdings LTD

Connect Biopharma announced its first quarter 2026 financial results, highlighting progress in its rademikibart clinical trials and a successful private placement financing.

Connect Biopharma's Phase 2 Seabreeze STAT trials for asthma and COPD will proceed without sample size changes following a positive interim analysis by the Data Monitoring Committee.

Connect Biopharma secured a $20.2 million private placement and reported encouraging IV rademikibart Phase 1 asthma/COPD data alongside strong 52-week Phase 3 atopic dermatitis results from partner Simcere.

Dr. Kan Chen has resigned from Connect Biopharma's Board of Directors, citing the company's successful strategic shift to a U.S.-centric model.

Connect Biopharma reported increased net losses in Q3 2025 despite progress in its rademikibart clinical trials and regulatory acceptance in China.

Connect Biopharma's CEO and President acquired significant shares, signaling confidence in the company's future.

Connect Biopharma Holdings Limited reported a net loss of $19.4 million for Q1 2026, with a significant increase in R&D expenses, offset by proceeds from a private placement that bolstered cash reserves.

Connect Biopharma reported a significant increase in net loss and cash burn for the nine months ended September 30, 2025, while advancing its lead drug candidate, rademikibart, into Phase 2 studies for asthma and COPD.

Connect Biopharma reported a significant net loss in Q2 2025 as research and development expenses increased, while advancing its lead asset rademikibart with positive clinical data and an NDA submission in China.

Connect Biopharma, a clinical-stage biopharmaceutical company, announced its financial results for the first quarter of 2025, highlighting progress in its rademikibart program and providing updates on recent developments.

Connect Biopharma reported a significant increase in net loss for 2025, while advancing its lead drug candidate, rademikibart, into Phase 2 trials for acute asthma and COPD, and securing a private placement for additional funding.

Connect Biopharma is prioritizing rademikibart for asthma and COPD, leveraging a partnership with Simcere in Greater China, according to its recent 10-K filing.

Kleanthis Xanthopoulos, a Director at Connect Biopharma Holdings Ltd, received 3,738 ordinary shares as compensation for his services.

Connect Biopharma Holdings Ltd reports that Director Jean I Liu received 6,718 ordinary shares as compensation for her services.

Director James Huang acquired 150,000 ordinary shares of Connect Biopharma Holdings Ltd. for approximately $356,610.

Director Kleanthis Xanthopoulos acquired 2,816 ordinary shares of Connect Biopharma Holdings Ltd in lieu of cash compensation.

Director Jean Liu acquired 5,061 ordinary shares of Connect Biopharma Holdings Ltd as compensation for board service.

Connect Biopharma Director James Huang has filed a Form 4 indicating a planned indirect acquisition of 1.16 million ordinary shares at $3.45 each on March 31, 2026, under a 10b5-1 plan.

Panacea Venture Healthcare Fund II, L.P. has reduced its beneficial ownership in Connect Biopharma Holdings Limited by selling 2,000,000 Ordinary Shares at $3.00 per share, now holding 21.5%.

Panacea Venture Healthcare Fund II, L.P. has increased its beneficial ownership in Connect Biopharma Holdings Limited to 25.1% through recent open market purchases of American Depositary Shares.

Wei Zheng has reported beneficial ownership of 3,876,036 ordinary shares, representing 6.2% of Connect Biopharma Holdings Ltd, as of March 31, 2026.

Biofortune Inc. and Wubin Pan report beneficial ownership of 9.5% and 9.6% respectively of Connect Biopharma Holdings Ltd. ordinary shares as of March 31, 2026.

Wei Zheng has reported an aggregate beneficial ownership of 9.9% in Connect Biopharma Holdings Ltd, totaling 5,527,528 ordinary shares.